5-Aza-2′-Deoxycytidine Alters the Methylation Profile of Bortezomib-Resistant U266 Multiple Myeloma Cells and Affects Their Proliferative Potential

Multiple myeloma (MM) is a plasma cell malignancy that accounts for 1% of all cancers and is the second-most-common hematological neoplasm. Bortezomib (BTZ) is a proteasome inhibitor widely implemented in the treatment of MM alone or in combination with other agents. The development of resistance to...

Full description

Bibliographic Details
Main Authors:	Karolina Łuczkowska, Piotr Kulig, Klaudia Rusińska, Bartłomiej Baumert, Bogusław Machaliński
Format:	Article
Language:	English
Published:	MDPI AG 2023-11-01
Series:	International Journal of Molecular Sciences
Subjects:	multiple myeloma bortezomib resistance methylation inhibitor 5-Aza-2′-deoxycytidine
Online Access:	https://www.mdpi.com/1422-0067/24/23/16780

Similar Items

Vitamin D and K Supplementation Is Associated with Changes in the Methylation Profile of U266-Multiple Myeloma Cells, Influencing the Proliferative Potential and Resistance to Bortezomib
by: Karolina Łuczkowska, et al.
Published: (2023-12-01)

Bortezomib-Induced Epigenetic Alterations in Nerve Cells: Focus on the Mechanisms Contributing to the Peripheral Neuropathy Development
by: Karolina Łuczkowska, et al.
Published: (2022-02-01)

The Evidence That 25(OH)D3 and VK2 MK-7 Vitamins Influence the Proliferative Potential and Gene Expression Profiles of Multiple Myeloma Cells and the Development of Resistance to Bortezomib
by: Karolina Łuczkowska, et al.
Published: (2022-12-01)

Hydralazine Sensitizes to the Antifibrotic Effect of 5-Aza-2′-deoxycytidine in Hepatic Stellate Cells
by: Kiyoshi Asada, et al.
Published: (2020-06-01)

Epigenetic Alterations as Vital Aspects of Bortezomib Molecular Action
by: Piotr Kulig, et al.
Published: (2023-12-01)

5-Aza-2′-Deoxycytidine and Valproic Acid in Combination with CHIR99021 and A83-01 Induce Pluripotency Genes Expression in Human Adult Somatic Cells
by: Alain Aguirre-Vázquez, et al.
Published: (2021-03-01)

A feline case of multiple myeloma treated with bortezomib
by: Hiroyuki Tani, et al.
Published: (2022-11-01)

Dataset on DNA methylation and gene expression changes induced by 5-aza-2′-deoxycytidine in Syrian golden hamster fetal cell cultures
by: Matthew J. Meier, et al.
Published: (2023-06-01)

Effective response with bortezomib retreatment in relapsed multiple myeloma
by: Christian Taverna, et al.
Published: (2012-04-01)

Evaluation of a Generic Bortezomib Molecule in Newly Diagnosed Multiple Myeloma Patients
by: Sinan Mersin, et al.
Published: (2021-08-01)

Long-Term Treatment with Bortezomib Induces Specific Methylation Changes in Differentiated Neuronal Cells
by: Karolina Łuczkowska, et al.
Published: (2022-07-01)

5-Aza-2’-deoxycytidine inhibits retinoblastoma cell by reactivating epigenetically silenced </b><i><b>RASSF1A</b></i><b> gene
by: Ru Liu, et al.
Published: (2014-02-01)

Results of multiple myeloma treatment with bortezomib
by: T. I. Pospelova, et al.
Published: (2022-11-01)

The Cost-Effectiveness Analysis of Transplant-Ineligible Myeloma Patients with Bortezomib plus Thalidomide plus Dexamethasone (VTD) or Bortezomib plus Melphalan plus Prednisolone (VMP) Treatment in Southern Taiwan
by: Jeng-Shiun Du, et al.
Published: (2022-01-01)

Combination of verteporfin-photodynamic therapy with 5-aza-2’-deoxycytidine enhances the anti-tumour immune response in triple negative breast cancer
by: Shramana M. Banerjee, et al.
Published: (2023-11-01)

Bortezomib neurotoxicity treatment of multiple myeloma: single center experience and literature review
by: N. V. Stepanova, et al.
Published: (2022-11-01)

Incidence, characteristics, and treatments of peripheral neuropathy in multiple myeloma patients receiving bortezomib (velcade)
by: S. S. Bessmeltsev, et al.
Published: (2022-11-01)

Prevention and management of bortezomib-induced peripheral neuropathy in patients with multiple myeloma
by: S. V. Semochkin, et al.
Published: (2022-04-01)

Management of Multiple Myeloma and Usage of Bortezomib: Perspective from India and Ukraine
by: India and Ukraine Haemato-oncology Group, et al.
Published: (2016-11-01)

Bortezomib-Induced Reticular Eruption in Patient with Multiple Myeloma
by: Joseph Han, et al.
Published: (2023-07-01)

Chalazia development in multiple myeloma: a new complication associated with bortezomib therapy
by: Charles Yun, et al.
Published: (2015-06-01)

Effect of 5-Aza-2'-deoxycytidine on the expression of Sfrp1 in NRK-52E cells cultured with high glucose
by: TIAN Ping-ping, NING Jie, ZOU Qin, LU Yu-wei, GUO Bing, SHI Ming-jun
Published: (2022-08-01)

Optimized Liposomal Delivery of Bortezomib for Advancing Treatment of Multiple Myeloma
by: Chi Zhang, et al.
Published: (2023-11-01)

Dose Adjustment Helps Obtain Better Outcomes in Multiple Myeloma Patients with Bortezomib, Melphalan, and Prednisolone (VMP) Treatment
by: Su-Hee Cho, et al.
Published: (2019-05-01)

Integrated analysis of randomized controlled trials evaluating bortezomib + lenalidomide + dexamethasone or bortezomib + thalidomide + dexamethasone induction in transplant-eligible newly diagnosed multiple myeloma
by: Laura Rosiñol, et al.
Published: (2023-11-01)

HDAC6-Selective Inhibitor Overcomes Bortezomib Resistance in Multiple Myeloma
by: Sang Wu Lee, et al.
Published: (2021-01-01)

Aberrant Gene Expression in Human Non Small Cell Lung Carcinoma Cells Exposed to Demethylating Agent 5-Aza-2'-Deoxycytidine
by: Bao-Zhu Yuan, et al.
Published: (2004-07-01)

Bortezomib Pharmacogenetic Biomarkers for the Treatment of Multiple Myeloma: Review and Future Perspectives
by: Antonio Sanz-Solas, et al.
Published: (2023-04-01)

Multiple myelomda kromozomal aberasyonlar: klinik sonuçlar ve bortezomib’ e yanıt
by: Arbil AÇIKALIN, et al.
Published: (2019-06-01)

Study on autonomic neuropathy of the digestive system caused by bortezomib in the treatment of multiple myeloma
by: Weiwei Zhao, et al.
Published: (2023-12-01)

Effect of bortezomib regimens and daratumumab monotherapy on cellular immunity in multiple myeloma patients
by: Ashraf Kakoo, et al.
Published: (2021-06-01)

Herpes zoster in multiple myeloma patients during bortezomib treatment
by: I. N. Nazarova, et al.
Published: (2014-07-01)

Herpes zoster in multiple myeloma patients during bortezomib treatment
by: I. N. Nazarova, et al.
Published: (2014-07-01)

Cytotoxic and Apoptotic Effects of Pinostilbene and Bortezomib Combination Treatment on Human Multiple Myeloma Cells
by: Anna Staskiewicz, et al.
Published: (2023-08-01)

The Effect of Thiamine in Reducing the Symptoms of Bortezomib-Induced Peripheral Neuropathy in Patients with Multiple Myeloma
by: Valiollah Mehrzad, et al.
Published: (2020-02-01)

Bortezomib therapy in a real-world setting in patients with relapsed or refractory multiple myeloma
by: Shang-Yi Huang, et al.
Published: (2019-01-01)

The Effect of Bortezomib Regimen on Multiple Myeloma Patients Infected with COVID-19
by: Zahra Rezaeian, et al.
Published: (2023-10-01)

Efficacy of lenalidomide, bortezomib, and prednisolone in patients with relapsed or refractory multiple myeloma
by: T. A. Мitinа, et al.
Published: (2015-12-01)

Multiple myeloma and kidney disease
by: Natalia Zarankiewicz, et al.
Published: (2022-08-01)

Relationship between Serum Bortezomib Concentration and Emergence of Diarrhea in Patients with Multiple Myeloma and/or AL Amyloidosis
by: Yuki Fujimoto, et al.
Published: (2021-11-01)